Ignyta Inc Cmn (RXDX) 5.90 $RXDX Ignyta Announc
Post# of 273258
Posted On: 09/02/2016 7:13:18 PM
Ignyta Inc Cmn (RXDX) 5.90 $RXDX
Ignyta Announces Approval of an Investigational Device Exemption (IDE) for the Companion Diagnostic Assay to the STARTRK-2 Trial
BusinessWire - Wed Aug 31, 6:00AM CDT
Ignyta, Inc. (Nasdaq: RXDX), a biotechnology company focused on precision medicine in oncology, today announced that the U.S. Food and Drug Administration (FDA) has approved an investigational device exemption (IDE) for its RNA-based companion diagnostic, next-generation sequencing (NGS) assay (Trailblaze Pharos(TM)). The Trailblaze Pharos assay is intended for use in identifying patients, including those who are treatment-naive, who have solid tumors with NTRK1/2/3, ROS1, or ALK gene rearrangements leading to fusion proteins, to determine eligibility for enrollment into the global STARTRK-2 trial, a Phase 2 study of entrectinib, a novel, orally available, CNS-penetrant tyrosine kinase inhibitor targeting tumors that harbor NTRK1/2/3 (encoding TrkA/TrkB/TrkC), ROS1, or ALK gene fusions.
RXDX: 5.90 (+0.02)
Ignyta Announces Second Quarter 2016 Company Highlights and Financial Results
BusinessWire - Tue Aug 09, 3:01PM CDT
Ignyta, Inc. (Nasdaq: RXDX), a biotechnology company focused on precision medicine in oncology, today announced company highlights and financial results for the second quarter ended June 30, 2016. Ignyta will not be conducting a conference call in conjunction with this release.
RXDX: 5.90 (+0.02)
Cleobrothers & Company, Inc. and PGC Solutions, Ltd. Form Joint Venture to Distribute, Market and Promote Cleobrothers Medication Products in Nigeria
BusinessWire - Fri Aug 05, 2:19PM CDT
Cleobrothers & Co., Inc. announced today that it signed a joint venture agreement with PGC Solutions, Ltd. to distribute, market and promote Cleobrothers branded products in Nigeria.
RXDX: 5.90 (+0.02)
Ignyta Announces Interim Data from Phase 1 Clinical Trial of Investigational Precision Medicine RXDX-105 at ASCO 2016
BusinessWire - Sun Jun 05, 8:00AM CDT
Ignyta, Inc. (Nasdaq: RXDX), a biotechnology company focused on precision medicine in oncology, today announced that interim results from the Phase 1 clinical trial of RXDX-105, the company's orally available, small molecule multikinase inhibitor with potent activity against such targets as RET and BRAF, were presented at the 2016 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago (Abstract 2574). RXDX-105 is Ignyta's second clinical stage compound after entrectinib, the furthest advanced inhibitor for solid tumors with NTRK (neurotrophin receptor kinase), ROS1, or ALK gene rearrangements.
RXDX: 5.90 (+0.02)
Ignyta to Present at 2016 Jefferies Healthcare Conference
BusinessWire - Thu May 26, 3:00PM CDT
Ignyta, Inc. (Nasdaq: RXDX), a precision oncology biotechnology company, announced today that Jonathan Lim., M.D., its Chairman and Chief Executive Officer, will make a presentation at the 2016 Jefferies Healthcare Conference on June 8, 2016 at 11:30 a.m. Eastern time (8:30 a.m. Pacific time) in New York, NY.
RXDX: 5.90 (+0.02)
Ignyta Announces RXDX-105 Phase 1 Data Presentation at the 2016 ASCO Annual Meeting
BusinessWire - Tue May 24, 3:00PM CDT
Ignyta, Inc. (Nasdaq: RXDX), a precision oncology biotechnology company, today announced the publication of an abstract for a poster session at the 2016 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Illinois. The abstract relates to the results of the Phase 1 clinical trial of RXDX-105, the company's orally available, small molecule multikinase inhibitor with potent activity against such targets as RET and BRAF. The poster session will be held on Sunday, June 5, 2016.
RXDX: 5.90 (+0.02)
Ignyta Reports Granting of Inducement Awards
BusinessWire - Mon May 16, 3:00PM CDT
Ignyta, Inc. (Nasdaq: RXDX), a precision oncology biotechnology company, announced today that it has issued inducement awards to two new non-executive employees.
RXDX: 5.90 (+0.02)
Ignyta Announces First Quarter 2016 Company Highlights and Financial Results
BusinessWire - Tue May 10, 3:00PM CDT
Ignyta, Inc. (Nasdaq: RXDX), a precision oncology biotechnology company, today announced company highlights and financial results for the first quarter ended March 31, 2016.
RXDX: 5.90 (+0.02)
Ignyta to Report 2016 First Quarter Company Highlights and Financial Results and Host Conference Call on May 10, 2016
BusinessWire - Wed May 04, 3:00PM CDT
Ignyta, Inc. (Nasdaq: RXDX), a precision oncology biotechnology company, today announced that it will release its first quarter 2016 financial results after the market closes on Tuesday, May 10, 2016. Ignyta management will host a conference call that same afternoon at 4:30 p.m. ET (1:30 p.m. PT) to provide company highlights, review the financial results and answer questions.
RXDX: 5.90 (+0.02)
Ignyta Announces Full Exercise of Underwriters' Option to Purchase Additional Shares
BusinessWire - Mon May 02, 6:00AM CDT
Ignyta, Inc. (Nasdaq: RXDX) ("Ignyta"
, a precision oncology biotechnology company, today announced that the underwriters of its previously announced underwritten public offering of 8.0 million shares of its common stock have exercised in full their option to purchase an additional 1.2 million shares at the public offering price of $6.25 per share, less underwriting discounts and commissions. The gross proceeds from the offering, including the option exercise, are expected to be $57.5 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Ignyta. The offering is expected to close on or about May 4, 2016, subject to customary closing conditions.
RXDX: 5.90 (+0.02)
Ignyta Announces Pricing of Public Offering of Common Stock
BusinessWire - Fri Apr 29, 5:00AM CDT
Ignyta, Inc. (Nasdaq: RXDX) ("Ignyta" , a precision oncology biotechnology company, today announced the pricing of an underwritten public offering of 8.0 million shares of its common stock at a price to the public of $6.25 per share. The gross proceeds from this offering are expected to be $50.0 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Ignyta. The offering is expected to close on or about May 4, 2016, subject to customary closing conditions. In addition, Ignyta has granted the underwriters a 30-day option to purchase up to an additional 1.2 million shares of its common stock at the public offering price, less the underwriting discounts and commissions in connection with the offering.
RXDX: 5.90 (+0.02)
Ignyta Announces Proposed Public Offering of Common Stock
BusinessWire - Wed Apr 27, 3:00PM CDT
Ignyta, Inc. (Nasdaq: RXDX) ("Ignyta" , a precision oncology biotechnology company, today announced that it has commenced an underwritten public offering to sell approximately $50.0 million of shares of its common stock. In connection with this offering, Ignyta expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering at the public offering price, less the underwriting discounts and commissions. The offering is subject to market and other conditions, and there can be no assurances as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
RXDX: 5.90 (+0.02)
Ignyta Announces Updated Data from Entrectinib Phase 1 Clinical Trials at the 2016 AACR Annual Meeting
BusinessWire - Sun Apr 17, 5:00PM CDT
Ignyta, Inc. (Nasdaq: RXDX), a precision oncology biotechnology company, today announced that updated results of its Phase 1 clinical trials of entrectinib, the company's proprietary oral tyrosine kinase inhibitor targeting solid tumors harboring activating alterations to NTRK1, NTRK2, NTRK3, ROS1 or ALK, were presented in an oral plenary session at the 2016 Annual Meeting of the American Association for Cancer Research (AACR) in New Orleans, Louisiana.
RXDX: 5.90 (+0.02)
Prometheus Diagnostic Test Validated in Anticipation of U.S. Healthcare Provider Demand for Celltrion's INFLECTRA(TM) (Biosimilar Infliximab)
PR Newswire - Thu Apr 07, 3:30PM CDT
Prometheus Laboratories Inc. announced today that the PROMETHEUS Anser IFX test has been validated for use in patients treated with INFLECTRA (biosimilar infliximab) in the management of inflammatory bowel disease (IBD). Validation was demonstrated using specimens from INFLECTRA-treated patients with IBD.
RXDX: 5.90 (+0.02), PFE: 34.77 (+0.09)
Ignyta Announces Oral Plenary Presentation and Poster Presentations at the 2016 AACR Annual Meeting
BusinessWire - Thu Apr 07, 3:00PM CDT
Ignyta, Inc. (Nasdaq: RXDX), a precision oncology biotechnology company, today announced the acceptance of an abstract for an oral plenary session presentation relating to its Phase 1 clinical development program for entrectinib, the company's proprietary oral tyrosine kinase inhibitor targeting solid tumors that harbor activating alterations to NTRK1, NTRK2, NTRK3, ROS1 or ALK, at the 2016 Annual Meeting of the American Association for Cancer Research (AACR) in New Orleans, Louisiana. The company also announced the acceptance of three other abstracts for poster presentations at the meeting, relating to entrectinib, the company's RXDX-107 product candidate, and a novel diagnostic statistical method to assess RNA expression.
RXDX: 5.90 (+0.02)
Salivary Gland Cancer Pipeline Review, H2 2015
M2 - Fri Feb 05, 4:22AM CST
Research and Markets (http://www.researchandmarkets.com/research/svqqnl/salivary_gland) has announced the addition of the "Salivary Gland Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Salivary Gland Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Salivary Gland Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Salivary Gland Cancer Overview - Therapeutics Development - Pipeline Products for Salivary Gland Cancer - Overview - Pipeline Products for Salivary Gland Cancer - Comparative Analysis - Salivary Gland Cancer - Therapeutics under Development by Companies - Salivary Gland Cancer - Therapeutics under Investigation by Universities/Institutes - Salivary Gland Cancer - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Salivary Gland Cancer - Products under Development by Companies - Salivary Gland Cancer - Products under Investigation by Universities/Institutes - Salivary Gland Cancer - Companies Involved in Therapeutics Development - AstraZeneca Plc - Bayer AG - Ignyta, Inc. - Loxo Oncology, Inc. - Otsuka Holdings Co., Ltd. - Plexxikon Inc. For more information visit http://www.researchandmarkets.com/research/sv...vary_gland
LOXO: 28.03 (+0.43), RXDX: 5.90 (+0.02), AZN: 33.31 (+0.71)
Ignyta Announces Initiation of Phase 1/1b Clinical Trial of Taladegib in Combination with Paclitaxel by Cancer Research UK
BusinessWire - Thu Feb 04, 6:00AM CST
Ignyta, Inc. (Nasdaq: RXDX), a precision oncology biotechnology company, today announced that Cancer Research UK has initiated a new, investigator-sponsored Phase 1/1b clinical trial of a combination of paclitaxel with taladegib - the company's novel, orally available, hedgehog/smoothened inhibitor - in patients with platinum-resistant, recurrent ovarian cancer or recurrent, advanced solid tumors. This clinical trial is an open label dose-escalation and expansion study designed to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), tolerability, pharmacokinetics and preliminary clinical activity of the combination of taladegib and weekly paclitaxel in this patient population. The lead investigator will be Dr. Rosalind Glasspool of the Beatson West of Scotland Cancer Centre, Glasgow, Scotland.
RXDX: 5.90 (+0.02)
Ignyta to Present at Leerink Partners 5th Annual Global Healthcare Conference
BusinessWire - Tue Feb 02, 6:00AM CST
Ignyta, Inc. (Nasdaq: RXDX), a precision oncology biotechnology company, announced today that Jacob Chacko, M.D., its Chief Financial Officer, will make a presentation at the Leerink Partners 5th Annual Global Healthcare Conference on Wednesday, February 10, 2016, at 11:55 a.m. Eastern time (8:55 a.m. Pacific time) in New York.
RXDX: 5.90 (+0.02)
Basal Cell Carcinoma (Basal Cell Epithelioma) Pipeline Review, H2 2015
M2 - Tue Feb 02, 5:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/hq8dm9/basal_cell) has announced the addition of the "Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Basal Cell Carcinoma Basal Cell Epithelioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Basal Cell Carcinoma Basal Cell Epithelioma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Basal Cell Carcinoma Basal Cell Epithelioma Overview - Therapeutics Development - Pipeline Products for Basal Cell Carcinoma Basal Cell Epithelioma - Overview - Pipeline Products for Basal Cell Carcinoma Basal Cell Epithelioma - Comparative Analysis - Basal Cell Carcinoma Basal Cell Epithelioma - Therapeutics under Development by Companies - Basal Cell Carcinoma Basal Cell Epithelioma - Therapeutics under Investigation by Universities/Institutes - Basal Cell Carcinoma Basal Cell Epithelioma - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Basal Cell Carcinoma Basal Cell Epithelioma - Products under Development by Companies - Basal Cell Carcinoma Basal Cell Epithelioma - Products under Investigation by Universities/Institutes - Basal Cell Carcinoma Basal Cell Epithelioma - Companies Involved in Therapeutics Development - 4SC AG - Biofrontera AG - Biosceptre (Aust) Pty Ltd - Genextra S.p.a. - Ignyta, Inc. - Laboratories Ojer Pharma S.L. - MediGene AG - Novartis AG - Redx Pharma Plc - Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Transgene SA For more information visit http://www.researchandmarkets.com/research/hq8dm9/basal_cell
RXDX: 5.90 (+0.02), NVS: 79.38 (+1.11)
Ignyta Announces Approval of an Investigational Device Exemption (IDE) for the Companion Diagnostic Assay to the STARTRK-2 Trial
BusinessWire - Wed Aug 31, 6:00AM CDT
Ignyta, Inc. (Nasdaq: RXDX), a biotechnology company focused on precision medicine in oncology, today announced that the U.S. Food and Drug Administration (FDA) has approved an investigational device exemption (IDE) for its RNA-based companion diagnostic, next-generation sequencing (NGS) assay (Trailblaze Pharos(TM)). The Trailblaze Pharos assay is intended for use in identifying patients, including those who are treatment-naive, who have solid tumors with NTRK1/2/3, ROS1, or ALK gene rearrangements leading to fusion proteins, to determine eligibility for enrollment into the global STARTRK-2 trial, a Phase 2 study of entrectinib, a novel, orally available, CNS-penetrant tyrosine kinase inhibitor targeting tumors that harbor NTRK1/2/3 (encoding TrkA/TrkB/TrkC), ROS1, or ALK gene fusions.
RXDX: 5.90 (+0.02)
Ignyta Announces Second Quarter 2016 Company Highlights and Financial Results
BusinessWire - Tue Aug 09, 3:01PM CDT
Ignyta, Inc. (Nasdaq: RXDX), a biotechnology company focused on precision medicine in oncology, today announced company highlights and financial results for the second quarter ended June 30, 2016. Ignyta will not be conducting a conference call in conjunction with this release.
RXDX: 5.90 (+0.02)
Cleobrothers & Company, Inc. and PGC Solutions, Ltd. Form Joint Venture to Distribute, Market and Promote Cleobrothers Medication Products in Nigeria
BusinessWire - Fri Aug 05, 2:19PM CDT
Cleobrothers & Co., Inc. announced today that it signed a joint venture agreement with PGC Solutions, Ltd. to distribute, market and promote Cleobrothers branded products in Nigeria.
RXDX: 5.90 (+0.02)
Ignyta Announces Interim Data from Phase 1 Clinical Trial of Investigational Precision Medicine RXDX-105 at ASCO 2016
BusinessWire - Sun Jun 05, 8:00AM CDT
Ignyta, Inc. (Nasdaq: RXDX), a biotechnology company focused on precision medicine in oncology, today announced that interim results from the Phase 1 clinical trial of RXDX-105, the company's orally available, small molecule multikinase inhibitor with potent activity against such targets as RET and BRAF, were presented at the 2016 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago (Abstract 2574). RXDX-105 is Ignyta's second clinical stage compound after entrectinib, the furthest advanced inhibitor for solid tumors with NTRK (neurotrophin receptor kinase), ROS1, or ALK gene rearrangements.
RXDX: 5.90 (+0.02)
Ignyta to Present at 2016 Jefferies Healthcare Conference
BusinessWire - Thu May 26, 3:00PM CDT
Ignyta, Inc. (Nasdaq: RXDX), a precision oncology biotechnology company, announced today that Jonathan Lim., M.D., its Chairman and Chief Executive Officer, will make a presentation at the 2016 Jefferies Healthcare Conference on June 8, 2016 at 11:30 a.m. Eastern time (8:30 a.m. Pacific time) in New York, NY.
RXDX: 5.90 (+0.02)
Ignyta Announces RXDX-105 Phase 1 Data Presentation at the 2016 ASCO Annual Meeting
BusinessWire - Tue May 24, 3:00PM CDT
Ignyta, Inc. (Nasdaq: RXDX), a precision oncology biotechnology company, today announced the publication of an abstract for a poster session at the 2016 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Illinois. The abstract relates to the results of the Phase 1 clinical trial of RXDX-105, the company's orally available, small molecule multikinase inhibitor with potent activity against such targets as RET and BRAF. The poster session will be held on Sunday, June 5, 2016.
RXDX: 5.90 (+0.02)
Ignyta Reports Granting of Inducement Awards
BusinessWire - Mon May 16, 3:00PM CDT
Ignyta, Inc. (Nasdaq: RXDX), a precision oncology biotechnology company, announced today that it has issued inducement awards to two new non-executive employees.
RXDX: 5.90 (+0.02)
Ignyta Announces First Quarter 2016 Company Highlights and Financial Results
BusinessWire - Tue May 10, 3:00PM CDT
Ignyta, Inc. (Nasdaq: RXDX), a precision oncology biotechnology company, today announced company highlights and financial results for the first quarter ended March 31, 2016.
RXDX: 5.90 (+0.02)
Ignyta to Report 2016 First Quarter Company Highlights and Financial Results and Host Conference Call on May 10, 2016
BusinessWire - Wed May 04, 3:00PM CDT
Ignyta, Inc. (Nasdaq: RXDX), a precision oncology biotechnology company, today announced that it will release its first quarter 2016 financial results after the market closes on Tuesday, May 10, 2016. Ignyta management will host a conference call that same afternoon at 4:30 p.m. ET (1:30 p.m. PT) to provide company highlights, review the financial results and answer questions.
RXDX: 5.90 (+0.02)
Ignyta Announces Full Exercise of Underwriters' Option to Purchase Additional Shares
BusinessWire - Mon May 02, 6:00AM CDT
Ignyta, Inc. (Nasdaq: RXDX) ("Ignyta"
, a precision oncology biotechnology company, today announced that the underwriters of its previously announced underwritten public offering of 8.0 million shares of its common stock have exercised in full their option to purchase an additional 1.2 million shares at the public offering price of $6.25 per share, less underwriting discounts and commissions. The gross proceeds from the offering, including the option exercise, are expected to be $57.5 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Ignyta. The offering is expected to close on or about May 4, 2016, subject to customary closing conditions. RXDX: 5.90 (+0.02)
Ignyta Announces Pricing of Public Offering of Common Stock
BusinessWire - Fri Apr 29, 5:00AM CDT
Ignyta, Inc. (Nasdaq: RXDX) ("Ignyta"
, a precision oncology biotechnology company, today announced the pricing of an underwritten public offering of 8.0 million shares of its common stock at a price to the public of $6.25 per share. The gross proceeds from this offering are expected to be $50.0 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Ignyta. The offering is expected to close on or about May 4, 2016, subject to customary closing conditions. In addition, Ignyta has granted the underwriters a 30-day option to purchase up to an additional 1.2 million shares of its common stock at the public offering price, less the underwriting discounts and commissions in connection with the offering. RXDX: 5.90 (+0.02)
Ignyta Announces Proposed Public Offering of Common Stock
BusinessWire - Wed Apr 27, 3:00PM CDT
Ignyta, Inc. (Nasdaq: RXDX) ("Ignyta"
, a precision oncology biotechnology company, today announced that it has commenced an underwritten public offering to sell approximately $50.0 million of shares of its common stock. In connection with this offering, Ignyta expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering at the public offering price, less the underwriting discounts and commissions. The offering is subject to market and other conditions, and there can be no assurances as to whether or when the offering may be completed, or as to the actual size or terms of the offering. RXDX: 5.90 (+0.02)
Ignyta Announces Updated Data from Entrectinib Phase 1 Clinical Trials at the 2016 AACR Annual Meeting
BusinessWire - Sun Apr 17, 5:00PM CDT
Ignyta, Inc. (Nasdaq: RXDX), a precision oncology biotechnology company, today announced that updated results of its Phase 1 clinical trials of entrectinib, the company's proprietary oral tyrosine kinase inhibitor targeting solid tumors harboring activating alterations to NTRK1, NTRK2, NTRK3, ROS1 or ALK, were presented in an oral plenary session at the 2016 Annual Meeting of the American Association for Cancer Research (AACR) in New Orleans, Louisiana.
RXDX: 5.90 (+0.02)
Prometheus Diagnostic Test Validated in Anticipation of U.S. Healthcare Provider Demand for Celltrion's INFLECTRA(TM) (Biosimilar Infliximab)
PR Newswire - Thu Apr 07, 3:30PM CDT
Prometheus Laboratories Inc. announced today that the PROMETHEUS Anser IFX test has been validated for use in patients treated with INFLECTRA (biosimilar infliximab) in the management of inflammatory bowel disease (IBD). Validation was demonstrated using specimens from INFLECTRA-treated patients with IBD.
RXDX: 5.90 (+0.02), PFE: 34.77 (+0.09)
Ignyta Announces Oral Plenary Presentation and Poster Presentations at the 2016 AACR Annual Meeting
BusinessWire - Thu Apr 07, 3:00PM CDT
Ignyta, Inc. (Nasdaq: RXDX), a precision oncology biotechnology company, today announced the acceptance of an abstract for an oral plenary session presentation relating to its Phase 1 clinical development program for entrectinib, the company's proprietary oral tyrosine kinase inhibitor targeting solid tumors that harbor activating alterations to NTRK1, NTRK2, NTRK3, ROS1 or ALK, at the 2016 Annual Meeting of the American Association for Cancer Research (AACR) in New Orleans, Louisiana. The company also announced the acceptance of three other abstracts for poster presentations at the meeting, relating to entrectinib, the company's RXDX-107 product candidate, and a novel diagnostic statistical method to assess RNA expression.
RXDX: 5.90 (+0.02)
Salivary Gland Cancer Pipeline Review, H2 2015
M2 - Fri Feb 05, 4:22AM CST
Research and Markets (http://www.researchandmarkets.com/research/svqqnl/salivary_gland) has announced the addition of the "Salivary Gland Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Salivary Gland Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Salivary Gland Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Salivary Gland Cancer Overview - Therapeutics Development - Pipeline Products for Salivary Gland Cancer - Overview - Pipeline Products for Salivary Gland Cancer - Comparative Analysis - Salivary Gland Cancer - Therapeutics under Development by Companies - Salivary Gland Cancer - Therapeutics under Investigation by Universities/Institutes - Salivary Gland Cancer - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Salivary Gland Cancer - Products under Development by Companies - Salivary Gland Cancer - Products under Investigation by Universities/Institutes - Salivary Gland Cancer - Companies Involved in Therapeutics Development - AstraZeneca Plc - Bayer AG - Ignyta, Inc. - Loxo Oncology, Inc. - Otsuka Holdings Co., Ltd. - Plexxikon Inc. For more information visit http://www.researchandmarkets.com/research/sv...vary_gland
LOXO: 28.03 (+0.43), RXDX: 5.90 (+0.02), AZN: 33.31 (+0.71)
Ignyta Announces Initiation of Phase 1/1b Clinical Trial of Taladegib in Combination with Paclitaxel by Cancer Research UK
BusinessWire - Thu Feb 04, 6:00AM CST
Ignyta, Inc. (Nasdaq: RXDX), a precision oncology biotechnology company, today announced that Cancer Research UK has initiated a new, investigator-sponsored Phase 1/1b clinical trial of a combination of paclitaxel with taladegib - the company's novel, orally available, hedgehog/smoothened inhibitor - in patients with platinum-resistant, recurrent ovarian cancer or recurrent, advanced solid tumors. This clinical trial is an open label dose-escalation and expansion study designed to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), tolerability, pharmacokinetics and preliminary clinical activity of the combination of taladegib and weekly paclitaxel in this patient population. The lead investigator will be Dr. Rosalind Glasspool of the Beatson West of Scotland Cancer Centre, Glasgow, Scotland.
RXDX: 5.90 (+0.02)
Ignyta to Present at Leerink Partners 5th Annual Global Healthcare Conference
BusinessWire - Tue Feb 02, 6:00AM CST
Ignyta, Inc. (Nasdaq: RXDX), a precision oncology biotechnology company, announced today that Jacob Chacko, M.D., its Chief Financial Officer, will make a presentation at the Leerink Partners 5th Annual Global Healthcare Conference on Wednesday, February 10, 2016, at 11:55 a.m. Eastern time (8:55 a.m. Pacific time) in New York.
RXDX: 5.90 (+0.02)
Basal Cell Carcinoma (Basal Cell Epithelioma) Pipeline Review, H2 2015
M2 - Tue Feb 02, 5:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/hq8dm9/basal_cell) has announced the addition of the "Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Basal Cell Carcinoma Basal Cell Epithelioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Basal Cell Carcinoma Basal Cell Epithelioma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Basal Cell Carcinoma Basal Cell Epithelioma Overview - Therapeutics Development - Pipeline Products for Basal Cell Carcinoma Basal Cell Epithelioma - Overview - Pipeline Products for Basal Cell Carcinoma Basal Cell Epithelioma - Comparative Analysis - Basal Cell Carcinoma Basal Cell Epithelioma - Therapeutics under Development by Companies - Basal Cell Carcinoma Basal Cell Epithelioma - Therapeutics under Investigation by Universities/Institutes - Basal Cell Carcinoma Basal Cell Epithelioma - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Basal Cell Carcinoma Basal Cell Epithelioma - Products under Development by Companies - Basal Cell Carcinoma Basal Cell Epithelioma - Products under Investigation by Universities/Institutes - Basal Cell Carcinoma Basal Cell Epithelioma - Companies Involved in Therapeutics Development - 4SC AG - Biofrontera AG - Biosceptre (Aust) Pty Ltd - Genextra S.p.a. - Ignyta, Inc. - Laboratories Ojer Pharma S.L. - MediGene AG - Novartis AG - Redx Pharma Plc - Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Transgene SA For more information visit http://www.researchandmarkets.com/research/hq8dm9/basal_cell
RXDX: 5.90 (+0.02), NVS: 79.38 (+1.11)
(0)
(0)Scroll down for more posts ▼